SCHEMBL8311548

SCHEMBL8311548

CC(=O)OC1CCc2ccc([N+](=O)[O-])cc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.46
CHRM4 P08173 4/20 0.46
HTR7 P34969 4/20 0.46
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR2A P28223 1/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
HIF1A Q16665 1/20 0.39
GRIN2B Q13224 1/20 0.39
PNMT P11086 3/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8308233 0.92 CHRM4 (0.47) DRD2CHRM4HTR7CYP3A4CYP2C9
SCHEMBL8312961 0.91 HSP90AA1 (0.46) DRD2CHRM4HTR7CYP3A4CYP2C9
SCHEMBL6988386 0.84 CYP3A4 (0.44) DRD2CYP3A4CYP2C9CYP2C19HSP90AA1
SCHEMBL28752620 0.82 POLB (0.41) DRD2HSP90AA1ALDH1A1L3MBTL1HTR2A
SCHEMBL8307594 0.80 HSD17B10 (0.43) ALDH1A1POLB
SCHEMBL13233999 0.77 HSP90AA1 (0.42) DRD2HSP90AA1HTR2AHIF1AGRIN2B
SCHEMBL5969938 0.77 CA12 (0.51) CYP3A4CYP2C9CYP2C19HSP90AA1RAB9A
SCHEMBL8307649 0.77 CHRM4 (0.49) DRD2CHRM4HTR7
SCHEMBL6616312 0.76 HSP90AA1 (0.49) DRD2HSP90AA1ALDH1A1HTR2AGRIN2B
SCHEMBL18339371 0.76 HSP90AA1 (0.49) DRD2HSP90AA1ALDH1A1HTR2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004087124-A1 COMPOUNDS HAVING SEROTONIN 5-HT17 RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M4 RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MITSUBISHI PHARMA CORPORATION (JP) 2004-10-14 WO disclosed